Let the Scientists Speak 3 FIGURE 3
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Preparedness: Responding to Biological Attacks, Pandemics, and Emerging Infec- Tious Disease Outbreaks
THE STATE OF U.S. PUBLIC HEALTH BIO- PREPAREDNESS: RESPONDING TO BIOLOGICAL ATTACKS, PANDEMICS, AND EMERGING INFEC- TIOUS DISEASE OUTBREAKS HEARING BEFORE THE SUBCOMMITTEE ON OVERSIGHT AND INVESTIGATIONS OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED FIFTEENTH CONGRESS SECOND SESSION FRIDAY, JUNE 15, 2018 Serial No. 115–140 ( Printed for the use of the Committee on Energy and Commerce energycommerce.house.gov U.S. GOVERNMENT PUBLISHING OFFICE 35–127 WASHINGTON : 2019 VerDate Nov 24 2008 13:47 Feb 28, 2019 Jkt 037690 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 U:\MY DOCS\HEARINGS 115\HEARINGS\115-140 CHRIS COMMITTEE ON ENERGY AND COMMERCE GREG WALDEN, Oregon Chairman JOE BARTON, Texas FRANK PALLONE, JR., New Jersey Vice Chairman Ranking Member FRED UPTON, Michigan BOBBY L. RUSH, Illinois JOHN SHIMKUS, Illinois ANNA G. ESHOO, California MICHAEL C. BURGESS, Texas ELIOT L. ENGEL, New York MARSHA BLACKBURN, Tennessee GENE GREEN, Texas STEVE SCALISE, Louisiana DIANA DEGETTE, Colorado ROBERT E. LATTA, Ohio MICHAEL F. DOYLE, Pennsylvania CATHY MCMORRIS RODGERS, Washington JANICE D. SCHAKOWSKY, Illinois GREGG HARPER, Mississippi G.K. BUTTERFIELD, North Carolina LEONARD LANCE, New Jersey DORIS O. MATSUI, California BRETT GUTHRIE, Kentucky KATHY CASTOR, Florida PETE OLSON, Texas JOHN P. SARBANES, Maryland DAVID B. MCKINLEY, West Virginia JERRY MCNERNEY, California ADAM KINZINGER, Illinois PETER WELCH, Vermont H. MORGAN GRIFFITH, Virginia BEN RAY LUJA´ N, New Mexico GUS M. BILIRAKIS, Florida PAUL TONKO, New York BILL JOHNSON, Ohio YVETTE D. CLARKE, New York BILLY LONG, Missouri DAVID LOEBSACK, Iowa LARRY BUCSHON, Indiana KURT SCHRADER, Oregon BILL FLORES, Texas JOSEPH P. -
Biden-Harris Transition Announces COVID-19 Advisory Board
BIDEN-HARRIS TRANSITION The President-Elect The Vice President-Elect Priorities Transition Español NOVEMBER 09, 2020 PRESS RELEASES Biden-Harris Transition Announces COVID-19 Advisory Board Leading Public Health and Scientific Experts to Advise the Transition on COVID-19 Response WASHINGTON – Today, the Biden-Harris Transition announced the formation of the Transition COVID-19 Advisory Board, a team of leading public health experts who will advise President-elect Biden, Vice President-elect Harris, and the Transition’s COVID-19 staff. The Transition COVID-19 Advisory Board will be led by co-chairs Dr. David Kessler, Dr. Vivek Murthy, and Dr. Marcella Nunez-Smith. Dr. Beth Cameron and Dr. Rebecca Katz are serving as advisors to the Transition on COVID-19 and will work closely with the Advisory Board. “Dealing with the coronavirus pandemic is one of the most important battles our administration will face, and I will be informed by science and by experts,” said President-elect Biden. “The advisory board will help shape my approach to managing the surge in reported infections; ensuring vaccines are safe, effective, and distributed efficiently, equitably, and free; and protecting at-risk populations.” New cases are rising in at least 40 states, with more than 9.3 million total infections and more than 236,000 deaths. President-elect Biden has pledged to bring leadership to the COVID pandemic, which continues to claim thousands of lives each week, by curbing the spread of the disease, providing free treatment to those in need, and elevating the voices of scientists and public health experts. The COVID-19 Advisory Board will help guide the Biden-Harris Transition in planning for the President-elect’s robust federal response. -
July 2020 Strategies for Emerging Infectious Diseases
THE AMERICAN WWW.CAYMANCHEM.COM ASSOCIATION OF IMMUNOLOGISTS AT ISSUE NEW THE DOWNLOAD Virus Life Cycle Infographic Infographic Cycle Life Virus JULY 2020 Resources for Your Research Your for Resources Informative Articles Informative CAYMAN CURRENTS: CAYMAN IN THIS ISSUE OF THE THE OF ISSUE THIS IN DISEASES INFECTIOUS EMERGING AAI Looks Back: How Honolulu’s Chinatown FOR STRATEGIES "Went Up in Smoke" A history of the first plague outbreak in Hawai’i, page 30 ANTIVIRAL 28 No. Permit CAYMAN CURRENTS PA Gettysburg, PAID 20852 20852 20852 20852 MD MD MD MD Rockville, Rockville, Rockville, Rockville, 650, 650, 650, 650, Suite Suite Suite Suite Pike, Pike, Pike, Pike, Rockville Rockville Rockville Rockville 1451 1451 1451 1451 Postage U.S. Non-Proft Org. Non-Proft IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS IMMUNOLOGISTS OF OF OF OF ASSOCIATION ASSOCIATION ASSOCIATION ASSOCIATION AMERICAN AMERICAN AMERICAN AMERICAN THE THE THE THE 2020 advanced Course in Immunology Now Virtual! I July 26–31, 2020 IN THIS ISSUE Director: Wayne M. Yokoyama, M.D. Washington University School of Medicine in St. Louis x4 Executive Offce The American Association Don’t miss the premier course in immunology for research scientists! of Immunologists x8 Public Affairs This intensive course is directed toward advanced trainees and scientists who wish to expand or update 1451 Rockville Pike, Suite 650 their understanding of the feld. Leading experts will present recent advances in the biology of the Rockville, MD 20852 20 Members in the News immune system and address its role in health and disease. This is not an introductory course; Tel: 301-634-7178 attendees will need to have a frm understanding of the principles of immunology. -
Speaker Bios
SPEAKER BIOGRAPHIES The Honorable Deborah Birx, MD Deborah L. Birx, MD is Ambassador-at-Large and Coordinator of the United States government activities to combat HIV/AIDS globally. Ambassador Birx is a world-renowned medical expert and leader in the field of HIV/AIDS whose three decade-long career has focused on HIV/AIDS immunology, vaccine research, and global health. As the U.S. Global AIDS Coordinator, Ambassador Birx oversees the implementation of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the largest commitment by any nation to combat a single disease in history, as well as all U.S. government engagement with the Global Fund to Fight AIDS, Tuberculosis, and Malaria. In 1985, Ambassador Birx began her career with the Department of Defense (DoD) as a military trained clinician in immunology, focusing on HIV/AIDS vaccine research. From 1985-1989 she served as an Assistant Chief of the Hospital Immunology Service at Walter Reed Army Medical Center. Through her professionalism and leadership in the field, she progressed to serve as the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research from 1996-2005. Ambassador Birx helped lead one of the most influential HIV vaccine trials in history (known as RV 144, or the Thai trial), which provided the first supporting evidence of any vaccine’s potential effectiveness in preventing HIV infection. During this time, she also rose to the rank of Colonel, bringing together the Navy, Army, and Air Force in a new model of cooperation – increasing the efficiency and effectiveness of the U.S. -
Coalition Communication: Healthcare
Updated 1/15/2021 Coalition Communication: Healthcare COVID-19 UPDATES We need your help in sharing information about the COVID-19 vaccine. KEY STATS Vaccine.coronavirus.ohio.gov is an online resource for Ohioans to learn which providers received a COVID-19 vaccine allotment and how to contact them. Data as of 1/14/2021 Tentative dates to start vaccinating these Phase 1B populations are: • Jan. 19, 2021—Ohioans 80 years of age and older. PUBLIC HEALTH • Jan. 25, 2021—Ohioans 75 years of age and older; those with severe ADVISORY SYSTEM congenital or developmental disorders. • Feb. 1, 2021—Ohioans 70 years of age and older; employees of K-12 schools that wish to remain or return to in-person or hybrid learning. • Feb. 8, 2021—Ohioans 65 years of age and older. When a new age group begins, vaccinations may not be complete for the previous age group. It will take a number of weeks to distribute all of the vaccines given the limited doses available. If you are older than 65, please connect with an Area Agencies on Aging about questions or if you need transportation assistance. For more information, visit aginig.ohio.gov or call 1-866-243-5678. More information can be found at coronavirus.ohio.gov. 21-DAY TRENDS INDUSTRY INFORMATION Case Average 7,316 ■ The Ad Council and the COVID Collaborative have released a series of Death Average 73 videos, available in a YouTube playlist, feature an introduction from Dr. Anthony Fauci and include experts leading healthcare organizations. Hospitalization 293 Average ■ BlackDoctor.org’s Making It Plain: What Black America Needs to Know ICU Admission 29 About COVID-19 and Vaccines aired on January 7 and is now available on- Average demand on YouTube. -
Do Vaccines Reduce Long-COVID Symptoms?
Do Vaccines Reduce Long-COVID Symptoms? One of the many important questions about long-COVID is whether COVID-19 vaccination can reduce symptoms in those experiencing long-COVID. While some patients report a lessening of symptoms, it is unknown whether this is causally related to the vaccine, or merely reflective of the fact that most patients’ symptoms improve over time. In addition, some patients also report a worsening of symptoms. But since there is currently a poor understanding of the causes and risk factors for long-COVID, all patient experiences following vaccination need to be carefully assessed. For example, one observational and uncontrolled study (not yet peer-reviewed) released in March 2021 compared 44 vaccinated long-COVID patients with 22 “I’ve heard from people who say they no longer matched unvaccinated participants. Those who received the vaccine showed a have ‘brain fog,’ their gastrointestinal problems small overall improvement in long-COVID symptoms, with a decrease in have gone away, or they stopped suffering from worsening symptoms (5.6% vaccinated vs. 14.2% unvaccinated) and increase in the shortness of breath they’ve been living with symptom resolution (23.2% vaccinated vs. 15.4% unvaccinated).1 Additionally, since being diagnosed with COVID-19.” an informal survey of more than 900 patients with long-COVID by Survivor - Akiko Iwasaki, PhD Corps, a patient advocacy group for those with long-COVID, found that only Professor of immunobiology at Yale School of 39% of patients reported improvements following vaccination. -
Notes from White House Briefing Call 6.10.2020
State, Local, and Tribal Leaders – Thank you to the State, local, and Tribal leaders who joined Vice President Mike Pence and Senior Administration Officials for the White House COVID-19 National Briefing Call on Wednesday, June 10. Attendees heard comprehensive updates and insights on continuing support for State, local, and Tribal response, recovery, and reopening efforts from Vice President Pence, Ambassador Deborah Birx (White House Coronavirus Task Force Coordinator), Secretary Ben Carson (U.S. Department of Housing and Urban Development), Secretary Eugene Scalia (U.S. Department of Labor), and Secretary Betsy DeVos (U.S. Department of Education). The Vice President also expressed his appreciation for the great work and sacrifice from America’s State, local, and Tribal leaders and also asked call attendees to share his, President Trump’s, and the entire Administration’s appreciation for our Nation’s first responders and healthcare workers. Find several examples from State and local leaders here, here, here, here, and here. Below, please find pertinent updates and a recap from the call. Recent Announcements President Trump Hosts Law Enforcement Roundtable: On Monday, President Trump held a roundtable discussion with law enforcement officials at the White House, where officers discussed responsible ideas for reform and ways for police officers to act as better friends for their communities. “There’s a reason for our less crime – it’s because we have great law enforcement. I’m very proud of them. There won’t be defunding, there won’t be dismantling of our police, and there are not going to be any disbanding of our police,” the President stated. -
COVID-19: a Weekly Health Care Update from Washington April 13-17, 2020
COVID-19: A Weekly Health Care Update from Washington April 13-17, 2020 IN BRIEF What Happened This Week: Negotiators failed to reach consensus on a proposal to provide additional support for small businesses this week (hospital funding was one of the major sticking points, although negotiations are progressing). Meanwhile, at the White House, President Trump and members of the Coronavirus Task Force unveiled the details of a new phased approach to “reopen” the nation’s the economy yesterday and instructed state governors to take the lead. What to Expect in the Weeks and Months Ahead: Expect lawmakers to continue negotiating a path forward for additional small business support; expect lawmakers to continue working remotely on additional measures tied to the pandemic; and expect the Trump Administration to continue providing clarity and guidance on the distribution of funds and implementation of other major provisions in the first three COVID-19 bills. DEEP DIVE President Trump Unveils “Guidelines for Opening Up America Again”; Instructs State Governors to Take the Lead on a Phased Reopening of the Economy President Trump and members of the White House Coronavirus Task Force unveiled the details of a new phased “reopening” of the nation’s economy using a “deliberate, data-driven approach.” The Administration leaves much of the decision-making to the states but instructs them to open up gradually after benchmarks on new cases, testing, and hospital resources are met. As far as timing goes, Coronavirus Task Force Response Coordinator Dr. Deborah Birx said there is no set schedule for any of the guideline’s three phases. -
Bio's Virtual Summit Advances Medical Countermeasure
BIO’S VIRTUAL SUMMIT ADVANCES MEDICAL COUNTERMEASURE PARTNERSHIPS FOR COVID-19 Launches Ongoing Initiative to Accelerate and Coordinate Development of Drugs, Vaccines, Preventives, and Diagnostics On March 24-25, 2020, BIO virtually convened more than 500 leaders from across industry, government, academia, and NGOs to assess the state of the pandemic and accelerate medical countermeasure solutions for COVID-19. BIO CEO Jim Greenwood and Dr. George Scangos, CEO of Vir, hosted the two-day summit to identify pressing technical, funding, regulatory and policy challenges, and enable BIO to catalyze cross- industry collaborations and public-private partnerships to advance development of medical countermeasures. Participants heard from key government officials, including Ambassador Deborah Birx, White House Coronavirus Response Coordinator, Dr. Robert Kadlec, HHS Assistant Secretary for Preparedness and Response, and Dr. Rick Bright, Director, Biomedical Advanced Research and Development Authority. KEY FINDINGS Based on Summit discussion, BIO identified the following critical needs and concerns: Successful development efforts will require the federal government to facilitate sharing of all relevant scientific and epidemiologic data and information as quickly and efficiently as possible. Many promising solutions will emerge from small and mid-sized companies and research laboratories, but these entities will likely have difficulty navigating the complex government contracting and regulatory bureaucracy; real-time assistance is needed. Early and rapid decisions from government funders will be essential to support immediate research, development, and clinical trial activity in order to identify the most promising candidates for further R&D and collaboration. Regulatory, advisory, and reimbursement authorities must be involved with requirement-setting and decision-making early on to prevent bottlenecks and downstream delays. -
Key Global Health Positions and Officials in the U.S. Government
January 2019 | Fact Sheet Key Global Health Positions and Officials in the U.S. Government Position Official WHITE HOUSE/EXECUTIVE OFFICE OF THE PRESIDENT Assistant to the President for National Security Affairs/National Security Advisor, National Security John Bolton Council (NSC) Senior Director for Weapons of Mass Destruction and Biodefense, NSC Tim Morrison Director for Medical and Biodefense Preparedness Policy, NSC Luciana Borio Director for Countering Biological Threats, NSC Hillary Carter Director for Global Health and International Development, NSC Peter Mamacos Special Assistant to the President; Senior Director for International Organizations and Alliances, Erin Walsh NSC Director, Office of Management and Budget (OMB) Mick Mulvaney Associate Director for National Security Programs, OMB Robert Blair Deputy Associate Director, International Affairs Division, National Security Programs, OMB Robert Fairweather Chief, Economic Affairs Branch, International Affairs Division, National Security Programs, OMB Fouad Saad Program Examiner, International Affairs Division, National Security Programs, OMB Will Cole Associate Director, Health Programs, OMB Joe Grogan Deputy Associate Director, Health Division, Health Programs, OMB Tom Reilly Chief, Public Health Branch, Health Programs, OMB Marc Garufi Program Examiner, Public Health Branch, Health Programs, OMB Nicholas Burton U.S. Trade Representative, Office of the United States Trade Representative (USTR) Robert Lighthizer Deputy U.S. Trade Representative, USTR C.J. Mahoney Assistant -
Coalition for Epidemic Preparedness Innovations New Vaccines for a Safer World
Coalition for Epidemic Preparedness Innovations New vaccines for a safer world Frederik Kristensen DCVMN Annual Meeting 25 October 2016 FOUNDING PARTNERS The challenge of epidemics Calls for global action CEPI - January - June Task Team Interim CEO High Level Task Team Leadership Meeting, Oslo appointed Meeting Tele- Group Meeting 6-7 April and constituted Davos conferences Washington DC Business Plan 21 January 17 May presented to stakeholders CEPI - July - September UNGA side Core Group First CEPI G7 Health event on health and CEPI soft interim board ministers’ side emergencies, Leadership launch meeting event, NY, Group Tele- Media London, Kobe, 19 September conferences coverage 31 August 10 September Challenges The pipeline is weak for most emerging infectious 1 diseases characterized by lack of market incentives Unilateral, uncoordinated government efforts to 2 fund R&D preparedness are inefficient and unsustainable in addressing global epidemic risks Clinical & regulatory pathways are not easily 3 adaptable to epidemic contexts Incentives are lacking to motivate 4 greater industry engagement Vaccine pipelines 45 40 35 30 25 20 15 10 5 0 Academic Government agency Biotech MNC Non-profits Preclinical Phase I Phase II Phase II/III Phase III Opportunities The Ebola momentum: vaccines are a feasible strategy, 1 despite a risky development pathway The Ebola momentum: it is possible to advance the 2 clinical development of safe and effective vaccines against EIDs in an emergency R&D actors supporting EID vaccine pipelines: 3 government health research agencies, academic research institutions, biotechs, vaccine manufacturers, and non-profits Manufacturing capability and capacity for vaccines has 4 always been a critical bottle-neck in epidemic events. -
What You Need to Know | President Trump's
From: Caliguiri, Laura To: Kimberly, Brad; Lynch, Sarah; Capobianco, Abigail Subject: FW: What You Need To Know | President Trump’s Coronavirus Response Efforts Date: Tuesday, March 31, 2020 8:53:05 PM From: Mitchell, Austin A. EOP/WHO (b) (6)@who.eop.gov> Sent: Tuesday, March 31, 2020 8:51 PM Subject: What You Need To Know | President Trump’s Coronavirus Response Efforts What You Need To Know | President Trump’s Coronavirus Response Efforts ________________________________ President Trump and his Administration are working every day to protect the health and wellbeing of Americans and respond to the coronavirus. WHOLE-OF-GOVERNMENT APPROACH The President signed the CARES Act, providing unprecedented and immediate relief to American families, workers, and businesses. President Trump declared a national emergency, inviting States, territories, and tribes to access over $42 billion in existing funding. President Trump signed initial legislation securing $8.3 billion for coronavirus response. President Trump signed the Families First Coronavirus Response Act, ensuring that American families and businesses impacted by the virus receive the strong support they need. To leverage the resources of the entire government, the President created a White House Coronavirus Task Force to coordinate response. The Vice President named Dr. Deborah Birx to serve as the White House Coronavirus Response Coordinator. At the request of President Trump, FEMA is leading federal operations on behalf of the White House Coronavirus Task Force. FEMA’s National Response Coordination Center has been activated to its highest level in support of coronavirus response. The President held a teleconference with other G20 leaders to coordinate coronavirus response.